Ticker VYGRListed on Nasdaq
Voyager Therapeutics, Inc.
At a glance
Most recent filing on November 3, 2026 — a grant by Carter Todd Alfred on Nov 1, 2026.
We hold 4 Form 4 lines, going back to November 3, 2026.
Insider trades
How to read a Form 4All 4 shown
- Carter Todd Alfred Chief Scientific Officer154,000 sharesGrant
- Carter Todd Alfred Chief Scientific Officer33,000 sharesGrant
- Swartz Robin President318,500 sharesGrant
- Swartz Robin President68,250 sharesGrant
CEO pay
What the company reported for its principal executive officer, usually the CEO, in the pay-versus-performance table of its proxy statement. The total counts shares and options at their value on the day they were granted. Actually paid counts them at the change in their value during the year, so it can be far higher or lower than the total, and negative. A dash means the company reported no amount.
Dr. Sandrock, fiscal year ended Dec 31, 2025: total $2,508,370, actually paid $2,050,563. First reported Apr 28, 2026.
Earlier fiscal years are part of the subscription.